IOVANCE BIOTHERAPEUTICS, INC. (IOVA) /
The cash flow of IOVANCE BIOTHERAPEUTICS, INC. over the past 10 years
Chart IOVANCE BIOTHERAPEUTICS, INC.: operating cash flow, capital expenditures, free cash flow, fiscal 2016–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, IOVANCE BIOTHERAPEUTICS, INC.'s operating cash flow was -$302.41M and its capital expenditures $33.84M, leaving free cash flow of -$336.24M. Free cash flow was below zero in all 10 years shown. It ranged from -$384.11M in fiscal 2023 to -$34.19M in fiscal 2016. Capital expenditures were highest in fiscal 2020, at $46.79M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$302.41M | $33.84M | -$336.24M |
| 2024ended Dec 31, 2024 | -$352.98M | $11.07M | -$364.05M |
| 2023ended Dec 31, 2023 | -$361.82M | $22.29M | -$384.11M |
| 2022ended Dec 31, 2022 | -$292.76M | $20.43M | -$313.18M |
| 2021ended Dec 31, 2021 | -$227.94M | $37.57M | -$265.51M |
| 2020ended Dec 31, 2020 | -$205.13M | $46.79M | -$251.93M |
| 2019ended Dec 31, 2019 | -$158.89M | $6.92M | -$165.81M |
| 2018ended Dec 31, 2018 | -$101.25M | $1.2M | -$102.45M |
| 2017ended Dec 31, 2017 | -$78.71M | $1.03M | -$79.74M |
| 2016ended Dec 31, 2016 | -$32.67M | $1.52M | -$34.19M |
Fiscal years as IOVANCE BIOTHERAPEUTICS, INC. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on IOVANCE BIOTHERAPEUTICS, INC.
- The revenue of IOVANCE BIOTHERAPEUTICS, INC.
- The profitability of IOVANCE BIOTHERAPEUTICS, INC.
- The debt of IOVANCE BIOTHERAPEUTICS, INC.
- All of IOVANCE BIOTHERAPEUTICS, INC.'s financials, charted
Companies of a similar size
- SMGScotts Miracle-Gro Co
- COCOThe Vita Coco Company, Inc.
- CNRCore Natural Resources, Inc.
- AZZAZZ Inc.
- KGSKodiak Gas Services, Inc.
Not investment advice. This page shows what IOVANCE BIOTHERAPEUTICS, INC. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.